Altogether, the concordant findings of the evaluation methods suggest that different platforms can be used for the investigation of both SEPT9 and SHOX2 methylation biomarkers for HNSCC patients. The gene discussed is SEPTIN9; the disease is head and neck squamous cell carcinoma.